Hormone receptors (HR), including estrogen (ER) and progesterone receptors (PR), are expressed in 70–75% of breast cancer (BC) cases and represent one of the cornerstones that direct the therapeutic decisions for patients with BC both in early and metastatic stages [1,2]. Here, PGR is linked to breast cancer.